Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
45
PCRX Quote, Financials, Valuation and Earnings
Last price:
$26.01
Seasonality move
:
13.08%
Day range:
$25.56 - $26.19
52-week range:
$18.17 - $27.64
Dividend yield:
0%
P/E ratio:
58.33x
P/S ratio:
1.68x
P/B ratio:
1.54x
Volume:
382.4K
Avg. volume:
801.1K
1-year change:
33.64%
Market cap:
$1.1B
Revenue:
$701M
EPS (TTM):
$0.45
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PCRX
Pacira Biosciences, Inc.
|
$182.3M | $0.65 | 6.9% | 175.21% | $29.71 |
|
ADMA
ADMA Biologics, Inc.
|
$130.5M | $0.16 | 18.97% | -56.04% | $25.67 |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$87M | -$0.09 | 53.91% | -88.43% | $31.63 |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
|
FOLD
Amicus Therapeutics, Inc.
|
$165.7M | $0.12 | 20.08% | 236.17% | $15.25 |
|
HOLX
Hologic, Inc.
|
$1B | $1.10 | 5.06% | 26.35% | $76.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PCRX
Pacira Biosciences, Inc.
|
$26.02 | $29.71 | $1.1B | 58.33x | $0.00 | 0% | 1.68x |
|
ADMA
ADMA Biologics, Inc.
|
$19.53 | $25.67 | $4.6B | 22.93x | $0.00 | 0% | 9.83x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$29.44 | $31.63 | $3.6B | -- | $0.00 | 0% | 11.83x |
|
CRMD
CorMedix, Inc.
|
$12.19 | $19.00 | $960.4M | 5.94x | $0.00 | 0% | 4.10x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.25 | $15.25 | $4.4B | -- | $0.00 | 0% | 7.29x |
|
HOLX
Hologic, Inc.
|
$74.50 | $76.50 | $16.6B | 30.00x | $0.00 | 0% | 4.13x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PCRX
Pacira Biosciences, Inc.
|
36.9% | -0.591 | 38.41% | 3.38x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -2.565 | 2.38% | 3.53x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
41.85% | -0.694 | 5.02% | 3.07x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | 0.379 | 18.22% | 1.91x |
|
HOLX
Hologic, Inc.
|
34.23% | 1.299 | 17.49% | 2.91x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PCRX
Pacira Biosciences, Inc.
|
$130.9M | $13.2M | 1.58% | 2.81% | 7.33% | $57M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$90.5M | $8.5M | -15.75% | -29.4% | 8.59% | -$1.8M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
HOLX
Hologic, Inc.
|
$580.7M | $253M | 7.59% | 11.59% | 24.11% | $324.7M |
Pacira Biosciences, Inc. vs. Competitors
-
Which has Higher Returns PCRX or ADMA?
ADMA Biologics, Inc. has a net margin of 3.03% compared to Pacira Biosciences, Inc.'s net margin of 27.14%. Pacira Biosciences, Inc.'s return on equity of 2.81% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital PCRXPacira Biosciences, Inc.72.93% $0.12 $1.2B ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About PCRX or ADMA?
Pacira Biosciences, Inc. has a consensus price target of $29.71, signalling upside risk potential of 14.2%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 31.69%. Given that ADMA Biologics, Inc. has higher upside potential than Pacira Biosciences, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Pacira Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PCRXPacira Biosciences, Inc.3 2 0 ADMAADMA Biologics, Inc.3 0 0 -
Is PCRX or ADMA More Risky?
Pacira Biosciences, Inc. has a beta of 0.233, which suggesting that the stock is 76.72% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.
-
Which is a Better Dividend Stock PCRX or ADMA?
Pacira Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira Biosciences, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCRX or ADMA?
Pacira Biosciences, Inc. quarterly revenues are $179.5M, which are larger than ADMA Biologics, Inc. quarterly revenues of $134.2M. Pacira Biosciences, Inc.'s net income of $5.4M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Pacira Biosciences, Inc.'s price-to-earnings ratio is 58.33x while ADMA Biologics, Inc.'s PE ratio is 22.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira Biosciences, Inc. is 1.68x versus 9.83x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCRXPacira Biosciences, Inc.1.68x 58.33x $179.5M $5.4M ADMAADMA Biologics, Inc.9.83x 22.93x $134.2M $36.4M
-
Which has Higher Returns PCRX or ARQT?
Arcutis Biotherapeutics, Inc. has a net margin of 3.03% compared to Pacira Biosciences, Inc.'s net margin of 7.47%. Pacira Biosciences, Inc.'s return on equity of 2.81% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.
Company Gross Margin Earnings Per Share Invested Capital PCRXPacira Biosciences, Inc.72.93% $0.12 $1.2B ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M -
What do Analysts Say About PCRX or ARQT?
Pacira Biosciences, Inc. has a consensus price target of $29.71, signalling upside risk potential of 14.2%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.63 which suggests that it could grow by 7.9%. Given that Pacira Biosciences, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe Pacira Biosciences, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PCRXPacira Biosciences, Inc.3 2 0 ARQTArcutis Biotherapeutics, Inc.5 1 0 -
Is PCRX or ARQT More Risky?
Pacira Biosciences, Inc. has a beta of 0.233, which suggesting that the stock is 76.72% less volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.693, suggesting its more volatile than the S&P 500 by 69.345%.
-
Which is a Better Dividend Stock PCRX or ARQT?
Pacira Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira Biosciences, Inc. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCRX or ARQT?
Pacira Biosciences, Inc. quarterly revenues are $179.5M, which are larger than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. Pacira Biosciences, Inc.'s net income of $5.4M is lower than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, Pacira Biosciences, Inc.'s price-to-earnings ratio is 58.33x while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira Biosciences, Inc. is 1.68x versus 11.83x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCRXPacira Biosciences, Inc.1.68x 58.33x $179.5M $5.4M ARQTArcutis Biotherapeutics, Inc.11.83x -- $99.2M $7.4M
-
Which has Higher Returns PCRX or CRMD?
CorMedix, Inc. has a net margin of 3.03% compared to Pacira Biosciences, Inc.'s net margin of 49.9%. Pacira Biosciences, Inc.'s return on equity of 2.81% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital PCRXPacira Biosciences, Inc.72.93% $0.12 $1.2B CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About PCRX or CRMD?
Pacira Biosciences, Inc. has a consensus price target of $29.71, signalling upside risk potential of 14.2%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 55.87%. Given that CorMedix, Inc. has higher upside potential than Pacira Biosciences, Inc., analysts believe CorMedix, Inc. is more attractive than Pacira Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PCRXPacira Biosciences, Inc.3 2 0 CRMDCorMedix, Inc.4 0 0 -
Is PCRX or CRMD More Risky?
Pacira Biosciences, Inc. has a beta of 0.233, which suggesting that the stock is 76.72% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock PCRX or CRMD?
Pacira Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira Biosciences, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCRX or CRMD?
Pacira Biosciences, Inc. quarterly revenues are $179.5M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Pacira Biosciences, Inc.'s net income of $5.4M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Pacira Biosciences, Inc.'s price-to-earnings ratio is 58.33x while CorMedix, Inc.'s PE ratio is 5.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira Biosciences, Inc. is 1.68x versus 4.10x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCRXPacira Biosciences, Inc.1.68x 58.33x $179.5M $5.4M CRMDCorMedix, Inc.4.10x 5.94x $104.3M $108.6M
-
Which has Higher Returns PCRX or FOLD?
Amicus Therapeutics, Inc. has a net margin of 3.03% compared to Pacira Biosciences, Inc.'s net margin of 10.24%. Pacira Biosciences, Inc.'s return on equity of 2.81% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital PCRXPacira Biosciences, Inc.72.93% $0.12 $1.2B FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About PCRX or FOLD?
Pacira Biosciences, Inc. has a consensus price target of $29.71, signalling upside risk potential of 14.2%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $15.25 which suggests that it could grow by 7.02%. Given that Pacira Biosciences, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Pacira Biosciences, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PCRXPacira Biosciences, Inc.3 2 0 FOLDAmicus Therapeutics, Inc.3 4 0 -
Is PCRX or FOLD More Risky?
Pacira Biosciences, Inc. has a beta of 0.233, which suggesting that the stock is 76.72% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.
-
Which is a Better Dividend Stock PCRX or FOLD?
Pacira Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira Biosciences, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCRX or FOLD?
Pacira Biosciences, Inc. quarterly revenues are $179.5M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Pacira Biosciences, Inc.'s net income of $5.4M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Pacira Biosciences, Inc.'s price-to-earnings ratio is 58.33x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira Biosciences, Inc. is 1.68x versus 7.29x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCRXPacira Biosciences, Inc.1.68x 58.33x $179.5M $5.4M FOLDAmicus Therapeutics, Inc.7.29x -- $169.1M $17.3M
-
Which has Higher Returns PCRX or HOLX?
Hologic, Inc. has a net margin of 3.03% compared to Pacira Biosciences, Inc.'s net margin of 17.85%. Pacira Biosciences, Inc.'s return on equity of 2.81% beat Hologic, Inc.'s return on equity of 11.59%.
Company Gross Margin Earnings Per Share Invested Capital PCRXPacira Biosciences, Inc.72.93% $0.12 $1.2B HOLXHologic, Inc.55.33% $0.83 $7.7B -
What do Analysts Say About PCRX or HOLX?
Pacira Biosciences, Inc. has a consensus price target of $29.71, signalling upside risk potential of 14.2%. On the other hand Hologic, Inc. has an analysts' consensus of $76.50 which suggests that it could grow by 2.69%. Given that Pacira Biosciences, Inc. has higher upside potential than Hologic, Inc., analysts believe Pacira Biosciences, Inc. is more attractive than Hologic, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PCRXPacira Biosciences, Inc.3 2 0 HOLXHologic, Inc.3 15 0 -
Is PCRX or HOLX More Risky?
Pacira Biosciences, Inc. has a beta of 0.233, which suggesting that the stock is 76.72% less volatile than S&P 500. In comparison Hologic, Inc. has a beta of 0.703, suggesting its less volatile than the S&P 500 by 29.745%.
-
Which is a Better Dividend Stock PCRX or HOLX?
Pacira Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hologic, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pacira Biosciences, Inc. pays -- of its earnings as a dividend. Hologic, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PCRX or HOLX?
Pacira Biosciences, Inc. quarterly revenues are $179.5M, which are smaller than Hologic, Inc. quarterly revenues of $1B. Pacira Biosciences, Inc.'s net income of $5.4M is lower than Hologic, Inc.'s net income of $187.3M. Notably, Pacira Biosciences, Inc.'s price-to-earnings ratio is 58.33x while Hologic, Inc.'s PE ratio is 30.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pacira Biosciences, Inc. is 1.68x versus 4.13x for Hologic, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PCRXPacira Biosciences, Inc.1.68x 58.33x $179.5M $5.4M HOLXHologic, Inc.4.13x 30.00x $1B $187.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
